"10.1371_journal.pone.0027704","plos one","2011-11-16T00:00:00Z","Marcel Kap; Frank Smedts; Wolter Oosterhuis; Rosa Winther; Nanna Christensen; Bilge Reischauer; Christian Viertler; Daniel Groelz; Karl-Friedrich Becker; Kurt Zatloukal; Rupert Langer; Julia Slotta-Huspenina; Koppany Bodo; Bas de Jong; Uwe Oelmuller; Peter Riegman","Department of Pathology, Josephine Nefkens Institute, Erasmus MC, Rotterdam, Netherlands; Dako, Research and Development, Glostrup, Denmark; Department of Pathology, Technical University of Munich, Munich, Germany; Institute of Pathology, Medical University of Graz, Graz, Austria; Qiagen, Research and Development, Hilden, Germany","Conceived and designed the experiments: UO MK CV BR FS WO KZ DG. Performed the experiments: MK CV BR DG. Analyzed the data: MK FS PR BdJ. Contributed reagents/materials/analysis tools: RW NC DG UO. Wrote the paper: MK PR FS WO BdJ CV KZ BR K-FB. Pathologists who evaluated the slides: FS RL JS-H KB.","The authors disclose the following: Daniel Grölz and Uwe Oelmüller are employed by QIAGEN and have stock options or bond holdings in the companys pension plan. The SPIDIA consortium is lead by Uwe Oelmüller, who is R&D director at Qiagen. The PAXgene fixative was developed by Qiagen-PreAnalytix and evaluated within the EU FP7 SPIDIA consortium. Rosa Winther and Nanna Christensen are employed by Dakocytomation. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2011","11","Marcel Kap","MK",16,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
